Skip to content
OpenCapital
Get started

Relmada Therapeutics, Inc. RLMD Indefinite-Lived Research and Development Assets

Indefinite-Lived Research and Development Assets at other companies

Merck & Co. logo
Merck & Co.MRK
$4.13B+35.0%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
——
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
——

Other financials

Income statement

See full
Operating income-$19.5M-6.8%
Net income-$19.1M-8.5%
EPS (diluted)-$0.22+62.1%

Balance sheet

See full
Cash & equivalents$9.8M+750%
Total debt$104.1M-40.4%
Total equity$218.7M+875%
Total assets$235.4M+750%

Cash flow

See full
Operating cash flow-$15.1M+16.6%

Valuation

See full
Market cap$677.17M+2,907%

Returns & leverage

See full
Return on equity-48.8%-20.0pp
Debt / equity0.9×0.0×
Current ratio18.3×+13.0×

Where this comes from

Reported directly by Relmada Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment.

The official record: Relmada Therapeutics, Inc.’s 10-K, filed March 19, 2026, on SEC EDGAR. View the filing →

Ask your AI about Relmada Therapeutics, Inc.'s indefinite-lived research and development assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Relmada Therapeutics, Inc.'s indefinite-lived research and development assets?
Relmada Therapeutics, Inc. (RLMD) reported indefinite-lived research and development assets of $4.77M in Q4 2025.
What does indefinite-lived research and development assets mean?
The carrying value of acquired in-process research and development (IPR&D) projects that are not yet amortized because their useful life is not determinable until the project is completed or abandoned. These assets represent the company's investment in future drug candidates and intellectual property. Changes in this balance often reflect impairment testing or the successful advancement of clinical programs.